Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

The global aHUS registry: methodology and initial patient characteristics.

Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Schaefer F, Vande Walle J, Frémeaux-Bacchi V.

BMC Nephrol. 2015 Dec 10;16:207. doi: 10.1186/s12882-015-0195-1.

2.

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.

Am J Kidney Dis. 2016 Jul;68(1):84-93. doi: 10.1053/j.ajkd.2015.12.034. Epub 2016 Mar 21.

3.

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.

Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C.

Kidney Int. 2016 Mar;89(3):701-11. doi: 10.1016/j.kint.2015.11.026. Epub 2016 Jan 28.

4.

An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry.

Woodward L, Johnson S, Walle JV, Beck J, Gasteyger C, Licht C, Ariceta G; aHUS Registry SAB.

Orphanet J Rare Dis. 2016 Nov 21;11(1):154. Review.

5.

[Atypical hemolytic uremic syndrome].

Blasco Pelicano M, Rodríguez de Córdoba S, Campistol Plana JM.

Med Clin (Barc). 2015 Nov 20;145(10):438-45. doi: 10.1016/j.medcli.2014.08.006. Epub 2014 Nov 26. Review. Spanish.

6.

Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients.

Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F.

BMC Nephrol. 2017 Jan 5;18(1):6. doi: 10.1186/s12882-016-0420-6.

7.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
8.

An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.

Sengul Samanci N, Ayer M, Ergen A, Ozturk S.

Transfus Apher Sci. 2015 Jun;52(3):314-6. doi: 10.1016/j.transci.2015.01.006. Epub 2015 Jan 12.

PMID:
25634788
9.

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.

Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N.

Intern Med J. 2015 Oct;45(10):1054-65. doi: 10.1111/imj.12864.

PMID:
26247170
10.

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.

Menne J, Delmas Y, Fakhouri F, Licht C, Lommelé Å, Minetti EE, Provôt F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA.

BMC Nephrol. 2019 Apr 10;20(1):125. doi: 10.1186/s12882-019-1314-1.

11.

Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome.

Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M.

Chest. 2017 Aug;152(2):424-434. doi: 10.1016/j.chest.2017.03.055. Epub 2017 Apr 23. Review.

12.

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.

J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.

13.

Atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N.

Transplantation. 2014 Dec 15;98(11):1205-12. doi: 10.1097/TP.0000000000000200.

PMID:
24933457
14.

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.

J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.

15.

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.

Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, Lommelé Å, Kupelian V, Gasteyger C, Greenbaum LA, Johnson S, Ogawa M, Licht C, Vande Walle J, Frémeaux-Bacchi V; Global aHUS Registry.

Kidney Int. 2018 Aug;94(2):408-418. doi: 10.1016/j.kint.2018.02.029. Epub 2018 Jun 19.

PMID:
29907460
16.

Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.

Rigothier C, Delmas Y, Roumenina LT, Contin-Bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-Bacchi V, Combe C.

Am J Kidney Dis. 2015 Aug;66(2):331-6. doi: 10.1053/j.ajkd.2015.03.039. Epub 2015 May 23.

PMID:
26015278
17.

Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.

Christmann M, Hansen M, Bergmann C, Schwabe D, Brand J, Schneider W.

Pediatrics. 2014 Jun;133(6):e1759-63. doi: 10.1542/peds.2013-1787.

PMID:
24843059
18.

Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.

Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.

Pediatrics. 2014 Jun;133(6):e1764-8. doi: 10.1542/peds.2013-1594.

PMID:
24843055
19.

[Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].

Kistler AD.

Praxis (Bern 1994). 2016 Mar 30;105(7):389-96. doi: 10.1024/1661-8157/a002308. Review. German.

PMID:
27005733
20.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

Supplemental Content

Support Center